Overview
Services

Human Metabolome Technologies,Inc.

Human Metabolome Technologies (HMT) is a Keio University-originated venture company specializing in metabolomics analysis services, leveraging proprietary Capillary Electrophoresis-Mass Spectrometry (CE-MS) technology to comprehensively measure ionic metabolites in biological samples. The company provides research support solutions across three key domains: life science research (biomarker discovery, mechanism of action elucidation), functional ingredient development (supporting functional food claims under Japan's functional labeling system), and bio-manufacturing support (optimizing microbial production processes for carbon-neutral manufacturing). HMT serves pharmaceutical, food, and biotechnology clients globally through its Japanese headquarters and a U.S. sales subsidiary, Human Metabolome Technologies America, Inc.

Market Cap
¥3.19B
US$20.4M
EV
¥1.80B
US$11.5M
Stock¥589▼-0.17%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
5.6
x
LTM EV/EBIT
8.6
x
LTM PER
16.0
x
LTM PBR
1.7
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-37.4%pt
10012
Oct 24, 25 – Oct 23, 26StockTOPIX
1Nov 13, 25Q2 earnings guidance downward revision
2Feb 16, 26New biomarker discovery announcement
MC → EV Bridge
3.19BUS$20.4MMarket Cap0.10BUS$0.66M+ Debt1.44BUS$9.21M− Cash0.05BUS$0.32M− Inv. Sec.1.80BUS$11.5MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
1.22US$7.80M'22/61.30US$8.28M'23/61.35US$8.58M'24/61.46US$9.28M'25/61.42US$9.06M'26/6
EBITDA 5Y (¥B)
0.26US$1.63M'22/60.29US$1.85M'23/60.31US$1.95M'24/60.35US$2.25M'25/60.32US$2.04M'26/6
Net Income 5Y (¥B)
0.27US$1.70M'22/60.29US$1.82M'23/60.24US$1.55M'24/60.26US$1.63M'25/60.20US$1.28M'26/6
Capital Structure
95%
EquityD/E 0.06xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
1.51US$9.64M0.23US$1.49M'22/61.66US$10.6M0.23US$1.44M'23/61.80US$11.5M0.23US$1.44M'24/61.61US$10.3M0.11US$0.70M'25/61.49US$9.53M0.10US$0.66M'26/6
Shareholders
Top 10 hold 35.2%
1
Masaru TOMITA
7.20%
2
MSIP CLIENT SECURITIES (Standing Proxy: Morgan Stanley MUFG Securities Co., Ltd.)
4.04%
3
M3,Inc.
4.01%
4
Tomoyoshi SOGA
3.84%
5
The Dai-ichi Life Insurance Company, Limited
3.43%
6
Takaaki NISHIOKA
2.77%
7
The Yamagata Bank,Ltd.
2.77%
8
Shonai Bank, Ltd.
2.77%
9
Nomura Securities Co., Ltd.
2.57%
10
Katsumi NARASAKI
1.85%
Management
5 officers
Yasuhiro OHATA
Representative Director, President
Apr 1988 Joined Procter & Gamble Far East, Inc. Jul 1999 Director, Classic Capital Corporation Co., Ltd. Apr 2001 Director, R2 Innovation Co., Ltd. Jan 2004 Representative Director, President, BT Company Co., Ltd. Apr 2008 Joined Takashima & Company, Limited as Director in charge of Corporate Planning Jun 2009 Director, General Manager of Corporate Planning Division, Takashima & Company, Limited Jun 2011 Managing Director, General Manager of Corporate Management Division, Takashima & Company, Limited Apr 2018 Director and Managing Executive Officer, General Manager of Industrial Solutions Business Division, Takashima & Company, Limited Jul 2020 Joined the Company as Executive Officer, General Manager of Corporate Division Sep 2020 Director, General Manager of Corporate Division (CFO) Apr 2024 Vice President, Director and CFO Jul 2024 President, Director and CFO Sep 2024 Representative Director, President and CFO (current)
1965-04-11
Kenjiro KAMI
Director
Nov 2012 Joined the Company, Research and Development Division Jul 2019 Executive Officer, General Manager of Analysis Division, Metabolomics Business Company Jul 2020 Executive Officer, in charge of Overseas Business Jul 2022 Executive Officer, in charge of Overseas Business and Metabolomics Center Apr 2024 Executive Officer, General Manager of Business Management Division Sep 2024 Director, General Manager of Business Management Division (current)
1975-06-06
Hajime NATSUKARI
Director (Audit and Supervisory Committee Member)
Dec 2008 Registered with the Tokyo Bar Association Dec 2008 Joined Matsuda Sogo Law Office Apr 2015 Part-time Lecturer, Tokyo Metropolitan University Law School Jan 2021 Partner, Matsuda Sogo Law Office (current) Jan 2022 Director, Fish and Planet Co., Ltd. (current) Sep 2022 Director (Audit and Supervisory Committee Member) of the Company (current)
1980-04-06
Hidehiro ANDO
Director (Audit and Supervisory Committee Member)
Apr 1980 Joined Tanabe Seiyaku Co., Ltd. Apr 2002 General Manager, Business Development Department, Stemcell Science Co., Ltd. Oct 2004 General Manager, Licensing Department, Bayer Yakuhin, Ltd. Dec 2012 General Manager, Business Development Division, Sosei Co., Ltd. Jul 2018 Part-time Audit & Supervisory Board Member, Lena Science Co., Ltd. Apr 2022 Representative, Andy Pharma Partners Co., Ltd. (current) Sep 2024 Director (Audit and Supervisory Committee Member) of the Company (current)
1955-04-07
Michiyo UJIIE
Director (Audit and Supervisory Committee Member)
Apr 1989 Joined Mitsui Finance Service Co., Ltd. Oct 1997 Joined Chuo Aoyama Audit Corporation Apr 2001 Registered as Certified Public Accountant Jan 2001 Assistant Certified Public Accountant; Head of Kawachi Office (now Ujiie CPA Office) (current) Jul 2010 Part-time work, Koa Audit Corporation Jun 2019 Outside Director (Audit and Supervisory Committee Member), Enomoto Co., Ltd. (current) Jul 2023 Partner, Koa Audit Corporation (current) Sep 2024 Director (Audit and Supervisory Committee Member) of the Company (current)
1966-02-22
Large Shareholding Reports
No filings
Disclosures
No disclosures
Primary Source Filings
EDINET
2026-09-17
Annual Securities Report
Period: Jul 2025 – Jun 2026
TDnet
2026-08-07
Full-Year Earnings Flash
FY ending Jun 2026
TDnet
2026-05-13
Q3 Earnings Flash
FY ending Jun 2026
EDINET
2026-02-12
Semi-Annual Securities Report
Period: Jul 2025 – Jun 2026
TDnet
2025-11-12
Q1 Earnings Flash
FY ending Jun 2026
EDINET
2025-09-22
Annual Securities Report
Period: Jul 2024 – Jun 2025
TDnet
2025-05-14
Q3 Earnings Flash
FY ending Jun 2025
EDINET
2025-02-13
Semi-Annual Securities Report
Period: Jul 2024 – Jun 2025
TDnet
2024-11-13
Q1 Earnings Flash
FY ending Jun 2025
EDINET
2024-09-24
Annual Securities Report
Period: Jul 2023 – Jun 2024
EDINET
2024-05-15
Quarterly Securities Report
Period: Jan 2024 – Mar 2024
EDINET
2024-02-14
Quarterly Securities Report
Period: Oct 2023 – Dec 2023
EDINET
2023-11-10
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-09-25
Annual Securities Report
Period: Jul 2022 – Jun 2023
EDINET
2023-05-12
Quarterly Securities Report
Period: Jan 2023 – Mar 2023
EDINET
2023-02-14
Quarterly Securities Report
Period: Oct 2022 – Dec 2022
EDINET
2022-11-11
Quarterly Securities Report
EDINET
2022-09-26
Annual Securities Report
EDINET
2022-05-13
Quarterly Securities Report
EDINET
2022-02-14
Quarterly Securities Report
EDINET
2021-11-12
Quarterly Securities Report
EDINET
2021-09-27
Annual Securities Report
EDINET
2021-05-12
Quarterly Securities Report
EDINET
2021-02-12
Quarterly Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →